메뉴 건너뛰기




Volumn 34, Issue 2, 1998, Pages 155-162

Clinical pharmacokinetics of fibric acid derivatives (Fibrates)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BEZAFIBRATE; CIPROFIBRATE; CYCLOSPORIN; CYTOCHROME P450; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GLIBENCLAMIDE; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; METFORMIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TOLBUTAMIDE; WARFARIN;

EID: 0031909536     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199834020-00003     Document Type: Article
Times cited : (240)

References (63)
  • 1
    • 0000637396 scopus 로고
    • Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate
    • Thorp JM, Waring WS. Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature 1962; 194: 948-9
    • (1962) Nature , vol.194 , pp. 948-949
    • Thorp, J.M.1    Waring, W.S.2
  • 2
    • 0026480744 scopus 로고
    • Relation of triglyceride metabolism and coronary artery disease: Studies in the postpradnial state
    • Patsch JR, Miesenbock G, Hopferweiser T, et al. Relation of triglyceride metabolism and coronary artery disease: studies in the postpradnial state. Arterioscler Throbm 1992; 12: 1336-45
    • (1992) Arterioscler Throbm , vol.12 , pp. 1336-1345
    • Patsch, J.R.1    Miesenbock, G.2    Hopferweiser, T.3
  • 3
    • 0026065576 scopus 로고
    • Plasma triglyceride and coronary heart disease
    • Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 11: 2-14
    • (1991) Arterioscler Thromb , vol.11 , pp. 2-14
    • Austin, M.A.1
  • 4
    • 0023726344 scopus 로고
    • Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
    • Manninen V, Elo O, Frick H, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641-51
    • (1988) JAMA , vol.260 , pp. 641-651
    • Manninen, V.1    Elo, O.2    Frick, H.3
  • 5
    • 0027445334 scopus 로고
    • Triglyceride-rich lipoproteins and atherosclerosis, from fast to feast
    • Steiner G. Triglyceride-rich lipoproteins and atherosclerosis, from fast to feast. Ann Med 1993; 25 (5): 431-5
    • (1993) Ann Med , vol.25 , Issue.5 , pp. 431-435
    • Steiner, G.1
  • 6
    • 0030455607 scopus 로고    scopus 로고
    • Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins
    • Gronholdt ML, Nordestgaard BG, Nielsen TG, et al. Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins. Stroke 1996; 27 (12): 2166-72
    • (1996) Stroke , vol.27 , Issue.12 , pp. 2166-2172
    • Gronholdt, M.L.1    Nordestgaard, B.G.2    Nielsen, T.G.3
  • 7
    • 0031049146 scopus 로고    scopus 로고
    • Effect of a single high-fat meal on endothelial function in healthy subjects
    • Vogel RA, Corretti M, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 1997; 79: 350-4
    • (1997) Am J Cardiol , vol.79 , pp. 350-354
    • Vogel, R.A.1    Corretti, M.2    Plotnick, G.D.3
  • 8
    • 0021276830 scopus 로고
    • Influence of gemfibrozil on metabolism of cholesterol and plasma triglycerides in man
    • Kesaniemi YA, Grundy SM. Influence of gemfibrozil on metabolism of cholesterol and plasma triglycerides in man. JAMA 1984; 251: 2241-6
    • (1984) JAMA , vol.251 , pp. 2241-2246
    • Kesaniemi, Y.A.1    Grundy, S.M.2
  • 9
    • 0017346450 scopus 로고
    • Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia
    • Nikkila EA, Huttunen JK, Ehnbolm C. Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia. Metabolism 1977; 26: 179-86
    • (1977) Metabolism , vol.26 , pp. 179-186
    • Nikkila, E.A.1    Huttunen, J.K.2    Ehnbolm, C.3
  • 10
    • 0017274039 scopus 로고
    • Gemfibrozil: Effect on serum lipids, lipoproteins, postheparin plasma lipase activities and gulcose tolerance in primary by pertriglyceridemia
    • Nikkila EA, Ylikahri R, Huttunen JK. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and gulcose tolerance in primary by pertriglyceridemia. Proc. R Soc Med 1776; 69 Suppl. 2: 58-63
    • (1776) Proc. R Soc Med , vol.69 , Issue.2 SUPPL. , pp. 58-63
    • Nikkila, E.A.1    Ylikahri, R.2    Huttunen, J.K.3
  • 11
    • 0029737127 scopus 로고    scopus 로고
    • Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days
    • Desager JP, Horsmans Y, Vandenplas C, et al. Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days. Atherosclerosis 1996; 124 Suppl.: S65-73
    • (1996) Atherosclerosis , vol.124 , Issue.SUPPL.
    • Desager, J.P.1    Horsmans, Y.2    Vandenplas, C.3
  • 12
    • 0026726877 scopus 로고
    • Delayed clearance of postprandial chylomicrons and their remnants in the hypoalphalipoproteinemia and mild hypertriglyceridemia syndrome
    • Ooi TC, Simo IE, Yakichuk JA. Delayed clearance of postprandial chylomicrons and their remnants in the hypoalphalipoproteinemia and mild hypertriglyceridemia syndrome. Arterioscler Thromb 1992; 12: 1184-90
    • (1992) Arterioscler Thromb , vol.12 , pp. 1184-1190
    • Ooi, T.C.1    Simo, I.E.2    Yakichuk, J.A.3
  • 13
    • 0019977898 scopus 로고
    • Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinemic subjects
    • Stewart JM, Packard CJ, Lorimer AR, et al. Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinemic subjects. Atherosclerosis 1982; 44: 355-65
    • (1982) Atherosclerosis , vol.44 , pp. 355-365
    • Stewart, J.M.1    Packard, C.J.2    Lorimer, A.R.3
  • 14
    • 0021853270 scopus 로고
    • Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease: Effects on metabolism of low-density lipoproteins
    • Vega GL, Grundy SM. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease: effects on metabolism of low-density lipoproteins. JAMA 1985; 253: 2398-403
    • (1985) JAMA , vol.253 , pp. 2398-2403
    • Vega, G.L.1    Grundy, S.M.2
  • 15
    • 0021824527 scopus 로고
    • Mechanism of action of gemfibrozil on lipoprotein metabolism
    • Saku K, Gartside PS, Hynd BA, et al. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest 1985; 75: 1702-12
    • (1985) J Clin Invest , vol.75 , pp. 1702-1712
    • Saku, K.1    Gartside, P.S.2    Hynd, B.A.3
  • 16
    • 0029587177 scopus 로고
    • Nonhormonal drugs and cancer
    • Stolley PD, Zahm SH. Nonhormonal drugs and cancer. Environ Health Perspect 1945; 103 Suppl. 8: 191-6
    • (1945) Environ Health Perspect , vol.103 , Issue.8 SUPPL. , pp. 191-196
    • Stolley, P.D.1    Zahm, S.H.2
  • 17
    • 0018117095 scopus 로고
    • A co-operative trial in the primary prevention of ischaemic heart disease: Report from the Committee of Principal Investigators
    • Oct
    • A co-operative trial in the primary prevention of ischaemic heart disease: report from the Committee of Principal Investigators. Br Heart J 1978 Oct; 40 (10): 1069-118
    • (1978) Br Heart J , vol.40 , Issue.10 , pp. 1069-1118
  • 18
    • 0028243020 scopus 로고
    • Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia
    • Larsen ML, Illingworth DR, O'Malley JP. Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia. Atherosclerosis 1994; 106 (2): 235-40
    • (1994) Atherosclerosis , vol.106 , Issue.2 , pp. 235-240
    • Larsen, M.L.1    Illingworth, D.R.2    O'Malley, J.P.3
  • 19
    • 0023262019 scopus 로고
    • Bezafibrate: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidemia
    • Monk JP, Todd PA. Bezafibrate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidemia. Drugs 1987; 33: 539-76
    • (1987) Drugs , vol.33 , pp. 539-576
    • Monk, J.P.1    Todd, P.A.2
  • 20
    • 0018954933 scopus 로고
    • Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure
    • Abshagen U, Kosters W, Kaufmann B, et al. Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure. Klin Wochenschrift 1980; 58: 889-96
    • (1980) Klin Wochenschrift , vol.58 , pp. 889-896
    • Abshagen, U.1    Kosters, W.2    Kaufmann, B.3
  • 21
    • 0018380599 scopus 로고
    • Disposition pharmacokinetics of bezafibrate in man
    • Abshagen U, Bablok W, Koch K, et al. Disposition pharmacokinetics of bezafibrate in man. Eur J Clin Pharmacol 1979; 16: 31-8
    • (1979) Eur J Clin Pharmacol , vol.16 , pp. 31-38
    • Abshagen, U.1    Bablok, W.2    Koch, K.3
  • 22
    • 0028110096 scopus 로고
    • The fibrates in clinical practice: Focus on micronised fenofibrate
    • Shepherd J. The fibrates in clinical practice: focus on micronised fenofibrate. Atherosclerosis 1994; 110: S55-63
    • (1994) Atherosclerosis , vol.110
    • Shepherd, J.1
  • 23
    • 0024369220 scopus 로고
    • The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate
    • Ferry N, Bernard N, Pozet N, et al. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate. Br J Clin Pharmacol 1989; 28: 675-81
    • (1989) Br J Clin Pharmacol , vol.28 , pp. 675-681
    • Ferry, N.1    Bernard, N.2    Pozet, N.3
  • 24
    • 0016589382 scopus 로고
    • Absorption and disposition of 2-[4-(2,2-dichlorocyclopropyl)-phenoxy]-2-methylpropanoic acid. Win 35.833, in rats, monkeys and men
    • Davison C, Benziger D, Fritz A, et al. Absorption and disposition of 2-[4-(2,2-dichlorocyclopropyl)-phenoxy]-2-methylpropanoic acid. WIN 35.833, in rats, monkeys and men. Drug Metab Dispos 1975; 3: 520-4
    • (1975) Drug Metab Dispos , vol.3 , pp. 520-524
    • Davison, C.1    Benziger, D.2    Fritz, A.3
  • 25
    • 0016582785 scopus 로고
    • Pharmacokinetics of drugs in patients with nephrotic syndrome
    • Gugler R, Shoeman DW, Huffman DH, et al. Pharmacokinetics of drugs in patients with nephrotic syndrome. J Clin Invest 1975; 55: 1182-9
    • (1975) J Clin Invest , vol.55 , pp. 1182-1189
    • Gugler, R.1    Shoeman, D.W.2    Huffman, D.H.3
  • 26
    • 0025128458 scopus 로고
    • Fenofibrate: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia
    • Balfour JA, McTavish D, Heel RC. Fenofibrate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 1990; 40: 260-90
    • (1990) Drugs , vol.40 , pp. 260-290
    • Balfour, J.A.1    McTavish, D.2    Heel, R.C.3
  • 27
    • 0019968477 scopus 로고
    • Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure
    • Desager JP, Costermans J, Verberckmoes R, et al. Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure. Nephron 1982; 31: 51-4
    • (1982) Nephron , vol.31 , pp. 51-54
    • Desager, J.P.1    Costermans, J.2    Verberckmoes, R.3
  • 29
    • 0018214469 scopus 로고
    • Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers
    • Desager JP, Harvengt C. Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers. Int J Clin Pharmacol Biopharm 1978; 16: 570-4
    • (1978) Int J Clin Pharmacol Biopharm , vol.16 , pp. 570-574
    • Desager, J.P.1    Harvengt, C.2
  • 31
    • 0022974507 scopus 로고
    • In vitro binding study of gemfibrozil to human serum proteins and erythrocytes: Interactions with other drugs
    • Hamberger C, Barre J, Zini R, et al. In vitro binding study of gemfibrozil to human serum proteins and erythrocytes: interactions with other drugs. Int J Clin Pharmacol Res 1986; 6: 441-9
    • (1986) Int J Clin Pharmacol Res , vol.6 , pp. 441-449
    • Hamberger, C.1    Barre, J.2    Zini, R.3
  • 33
    • 0027536797 scopus 로고
    • Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. II: Multiple-dose administration and chronopharmacokinetics
    • Vens-Cappell B, Berndt P, Hilgenstock C, et al. Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. II: multiple-dose administration and chronopharmacokinetics. Arzneimittel Forschung 1993; 43: 351-6
    • (1993) Arzneimittel Forschung , vol.43 , pp. 351-356
    • Vens-Cappell, B.1    Berndt, P.2    Hilgenstock, C.3
  • 34
    • 0027413864 scopus 로고
    • Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. I: Single-dose administration
    • Vens-Cappell B, Hilgenstock C, Gellert M, et al. Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. I: single-dose administration. Arzneimittel Forschung 1993; 43: 346-50
    • (1993) Arzneimittel Forschung , vol.43 , pp. 346-350
    • Vens-Cappell, B.1    Hilgenstock, C.2    Gellert, M.3
  • 35
    • 0027363780 scopus 로고
    • A comparison of the bioavailability of standard or micronized formulations of fenofibrate
    • Guichard JP, Levy-Prades Sauron R. A comparison of the bioavailability of standard or micronized formulations of fenofibrate. Curr Ther Res 1993; 54: 610-4
    • (1993) Curr Ther Res , vol.54 , pp. 610-614
    • Guichard, J.P.1    Levy-Prades Sauron, R.2
  • 36
    • 6844261317 scopus 로고
    • Fournier Pharma Inc., Montreal (Canada)
    • Lipidil product monograph. Fournier Pharma Inc., Montreal (Canada), 1990
    • (1990) Lipidil Product Monograph
  • 37
    • 1842605278 scopus 로고
    • Effect of time of dosing on the pharmacokinetics of a controlled-release gemfibrozil tablet (Lopid SR)
    • Cook JA, Rajagopalan R, Eldon MA, et al. Effect of time of dosing on the pharmacokinetics of a controlled-release gemfibrozil tablet (Lopid SR). Pharmacol Res 1991; 8 Suppl.: S296
    • (1991) Pharmacol Res , vol.8 , Issue.SUPPL.
    • Cook, J.A.1    Rajagopalan, R.2    Eldon, M.A.3
  • 38
    • 1842448530 scopus 로고
    • Gemfibrozil pharmacokinetics after multiple-dose administration of controlled-release (Lopid SR) and conventional (Lopid) tablets
    • Cook JA, Eldon MA, Gibson DM, et al. Gemfibrozil pharmacokinetics after multiple-dose administration of controlled-release (Lopid SR) and conventional (Lopid) tablets. Pharmacol Res 1992; 9 Suppl.: S325
    • (1992) Pharmacol Res , vol.9 , Issue.SUPPL.
    • Cook, J.A.1    Eldon, M.A.2    Gibson, D.M.3
  • 39
    • 0028576943 scopus 로고
    • Interactions of warfarin with drugs and food
    • see comments in: ACP J Club 1995; 122 (2): 44.
    • Wells PS, Holbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food [see comments in: ACP J Club 1995; 122 (2): 44]. Ann Intern Med 1994; 121 (9): 676-83
    • (1994) Ann Intern Med , vol.121 , Issue.9 , pp. 676-683
    • Wells, P.S.1    Holbrook, A.M.2    Crowther, N.R.3
  • 40
    • 0023677227 scopus 로고
    • Gemfibrozil: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidemia
    • Todd PA, Ward A. Gemfibrozil: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidemia. Drugs 1988; 36: 314-39
    • (1988) Drugs , vol.36 , pp. 314-339
    • Todd, P.A.1    Ward, A.2
  • 41
    • 0025104039 scopus 로고
    • Gemfibrozil interaction with warfarin sodium (coumadin)
    • Ahmad S. Gemfibrozil interaction with warfarin sodium (coumadin). Chest 1990; 98: 1041-2
    • (1990) Chest , vol.98 , pp. 1041-1042
    • Ahmad, S.1
  • 42
    • 0026514173 scopus 로고
    • Severe gastrointestinal bleeding induced by a probable hydroxycoumarin-bezafibrate interaction
    • Blum A, Livneh A, Seligmann H. Severe gastrointestinal bleeding induced by a probable hydroxycoumarin-bezafibrate interaction. Isr J Med Sci 1992; 28: 47-9
    • (1992) Isr J Med Sci , vol.28 , pp. 47-49
    • Blum, A.1    Livneh, A.2    Seligmann, H.3
  • 43
    • 0017816548 scopus 로고
    • Effect of short-term clofibrate on glucose metabolism and insulin secretion in patients with mild maturity-onset diabetes mellitus
    • Ferrari C, Romussu M, Testori GP, et al. Effect of short-term clofibrate on glucose metabolism and insulin secretion in patients with mild maturity-onset diabetes mellitus. Biomedicine 1978; 29: 133-6
    • (1978) Biomedicine , vol.29 , pp. 133-136
    • Ferrari, C.1    Romussu, M.2    Testori, G.P.3
  • 45
    • 0026083568 scopus 로고
    • Gemfibrozil: Interaction with glyburide
    • Ahmad S. Gemfibrozil: interaction with glyburide. South Med J 1991; 84: 102
    • (1991) South Med J , vol.84 , pp. 102
    • Ahmad, S.1
  • 46
    • 0025365041 scopus 로고
    • Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
    • Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71-5
    • (1990) JAMA , vol.264 , pp. 71-75
    • Pierce, L.R.1    Wysowski, D.K.2    Gross, T.P.3
  • 47
    • 0028962401 scopus 로고
    • Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety
    • Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995; 16: 5-13
    • (1995) Eur Heart J , vol.16 , pp. 5-13
    • Shepherd, J.1
  • 48
    • 0029042641 scopus 로고
    • Pharmacokinetics of the combination of fluvastatin and gemfibrozil
    • Spence JD, Munoz CE, Hendricks L. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995; 76: 80-3
    • (1995) Am J Cardiol , vol.76 , pp. 80-83
    • Spence, J.D.1    Munoz, C.E.2    Hendricks, L.3
  • 49
    • 0029166810 scopus 로고
    • Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors
    • Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 1995; 52 (15): 1639-45
    • (1995) Am J Health Syst Pharm , vol.52 , Issue.15 , pp. 1639-1645
    • Garnett, W.R.1
  • 50
    • 0029758869 scopus 로고    scopus 로고
    • Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
    • Neuvonen PJ, Jalava K-M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996; 60: 54-61
    • (1996) Clin Pharmacol Ther , vol.60 , pp. 54-61
    • Neuvonen, P.J.1    Jalava, K.-M.2
  • 51
    • 12644251055 scopus 로고    scopus 로고
    • Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses
    • Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62: 311-21
    • (1997) Clin Pharmacol Ther , vol.62 , pp. 311-321
    • Olbricht, C.1    Wanner, C.2    Eisenhauer, T.3
  • 52
    • 0028846142 scopus 로고
    • In vivo inhibition profile of cyctochrome P450TB (CYP2C9) by (+/-)-fluvastatin
    • Transon C, Leemann T, Vogt N, et al. In vivo inhibition profile of cyctochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther 1995; 58 (4): 412-7
    • (1995) Clin Pharmacol Ther , vol.58 , Issue.4 , pp. 412-417
    • Transon, C.1    Leemann, T.2    Vogt, N.3
  • 53
    • 0027321524 scopus 로고
    • Biotransformation of pravastatin sodium (I): Mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium
    • Kitazawa E, Tamura N, Iwabuchi H, et al. Biotransformation of pravastatin sodium (I): mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium. Biochem Biophys Res Commun 1993; 192: 597-602
    • (1993) Biochem Biophys Res Commun , vol.192 , pp. 597-602
    • Kitazawa, E.1    Tamura, N.2    Iwabuchi, H.3
  • 54
    • 0030944304 scopus 로고    scopus 로고
    • Drug interactions with grapefruit: Whose responsibility is it to warn the public?
    • Spence JD. Drug interactions with grapefruit: whose responsibility is it to warn the public? Clin Pharmacol Ther 1997; 61: 395-400
    • (1997) Clin Pharmacol Ther , vol.61 , pp. 395-400
    • Spence, J.D.1
  • 55
    • 0023929374 scopus 로고
    • Rhabdomyolysis and renal injury with lovastatin use: Report of two cases in cardiac transplant recipients
    • Corpier CI, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA 1988; 260: 239-41
    • (1988) JAMA , vol.260 , pp. 239-241
    • Corpier, C.I.1    Jones, P.H.2    Suki, W.N.3
  • 56
    • 0023860312 scopus 로고
    • Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation
    • East C, Alivizatos PA, Grundy SC, et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988; 318: 47-8
    • (1988) N Engl J Med , vol.318 , pp. 47-48
    • East, C.1    Alivizatos, P.A.2    Grundy, S.C.3
  • 57
    • 0029126528 scopus 로고
    • Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole
    • Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995; 333: 664-5
    • (1995) N Engl J Med , vol.333 , pp. 664-665
    • Lees, R.S.1    Lees, A.M.2
  • 59
    • 0029089702 scopus 로고
    • Ketoconazole to reduce the need for cyclosporine after cardiac transplantation
    • Keogh A, Spratt P, McCosker C, et al. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 1995; 333: 628-33
    • (1995) N Engl J Med , vol.333 , pp. 628-633
    • Keogh, A.1    Spratt, P.2    McCosker, C.3
  • 60
    • 0026099498 scopus 로고
    • Interaction of citrus juices with felodipine and nifedipine
    • Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-9
    • (1991) Lancet , vol.337 , pp. 268-269
    • Bailey, D.G.1    Spence, J.D.2    Munoz, C.3
  • 61
    • 0028153858 scopus 로고
    • Grapefruit juice and drugs: How significant is the interaction?
    • Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokinet 1994; 26 (2): 91-8
    • (1994) Clin Pharmacokinet , vol.26 , Issue.2 , pp. 91-98
    • Bailey, D.G.1    Arnold, J.M.O.2    Spence, J.D.3
  • 62
    • 0030897505 scopus 로고    scopus 로고
    • Grapefruit juice: Terfenadine single-dose interaction: magnitude, mechanism, and relevance
    • Rau SE, Bend JR, Arnold MO, et al. Grapefruit juice: terfenadine single-dose interaction: magnitude, mechanism, and relevance. Pharmacokinet Drug Dispos 1997; 61: 401-9
    • (1997) Pharmacokinet Drug Dispos , vol.61 , pp. 401-409
    • Rau, S.E.1    Bend, J.R.2    Arnold, M.O.3
  • 63
    • 0029782647 scopus 로고    scopus 로고
    • Erythromycin-felodipine interaction: Magnitude, mechanism and comparison with grapefruit juice
    • Jul
    • Bailey DG, Bend JR, Arnold JMO, et al. Erythromycin-felodipine interaction: magnitude, mechanism and comparison with grapefruit juice. Clin Pharmacol Ther 1996 Jul; 60 (1): 25-33
    • (1996) Clin Pharmacol Ther , vol.60 , Issue.1 , pp. 25-33
    • Bailey, D.G.1    Bend, J.R.2    Arnold, J.M.O.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.